Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|November 17, 2026 (Updated: November 17, 2026)

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing

FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: a new option beyond steroids, a cancer vaccine that extended survival in phase 3, and a well-funded bet on treating blood disorders without stem cell transplants.

First, FDA has approved Novartis’ Cosentyx for adults with polymyalgia rheumatica who have an inadequate response to corticosteroids or cannot tolerate a corticosteroid taper. It is the first anti-IL-17 biologic approved for the disease and Cosentyx’s 11th US indication. In the phase 3 REPLENISH trial, sustained remission at week 52 was about 41% with secukinumab versus about 20% with placebo. Patients on secukinumab also needed less steroid.

Next, SELLAS Life Sciences says its cancer vaccine galinpepimut-S met its primary endpoint in the phase 3 REGAL trial in acute myeloid leukemia. It is an off-the-shelf, WT1-targeted peptide cancer vaccine, tested as maintenance therapy in patients in second or later remission who could not undergo a transplant. Median overall survival was 24.0 months with the vaccine versus 14.7 months with best available treatment. The trial was open-label and the results are topline. SELLAS is targeting a BLA in the first half of 2027. www.biopharminternational.com

And finally, Marrow Therapeutics has launched with $173 million in combined Series A and B financing. Its platform uses engineered antibodies that target the transferrin receptor in bone marrow to deliver therapeutic payloads. The lead program, MAR-101, aims to reactivate fetal hemoglobin for sickle cell disease and beta thalassemia, without the stem cell collection and conditioning that ex vivo gene therapies require. It is in IND-enabling studies.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Steroid sparing: Cosentyx is now the second biologic approved for polymyalgia rheumatica, joining sarilumab.
  • Survival benefit: REGAL is a rare phase 3 overall survival win for a peptide cancer vaccine, though the full data haven’t been peer reviewed.
  • In vivo delivery: Marrow is betting antibody-guided delivery can reach blood stem cells without transplant, which hasn’t been shown in humans yet.

Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.